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Abstract
Introduction Pharmaceutical risk minimization programs
involve interventions designed to support safe and appro-
priate use of medicines. Currently, information regarding
the evaluation of these programs is not publicly reported in
a standardized and transparent manner. To address this gap,
we developed and piloted a quality reporting checklist
entitled the Reporting recommendations Intended for
pharmaceutical risk Minimization Evaluation Studies
(RIMES).
Methods Checklist development was guided by three
sources: (1) a theoretical framework derived from program
theory and process evaluation; (2) public health interven-
tion design and evaluation principles; and (3) a review of
existing quality reporting checklists. Two raters indepen-
dently reviewed 10 recently published (2012–2016) risk
minimization program evaluation studies using the pro-
posed checklist. Inter-rater reliability of the checklist was
assessed using Cohen’s Kappa and Gwet’s AC1.
Results A 43-item checklist was generated. Results indi-
cated substantial inter-rater reliability overall (j = 0.65,
AC1 = 0.65) and for three (key information, design and
evaluation) of the four subscales (jC 0.64, AC1C 0.64).
The fourth subscale (implementation) showed low relia-
bility based on Cohen’s Kappa, but substantial reliability
based on the AC1 (j = 0.17, AC1 = 0.61).
Conclusions The RIMES statement augments relevant
elements from existing quality reporting guidelines with
items that address aspects of intervention design, imple-
mentation and evaluation specific to pharmaceutical risk
minimization programs. Our results show that the RIMES
statement reliably measures key dimensions of reporting
quality. This tailored checklist is an important first step in
improving the reporting quality of risk minimization
evaluation studies and may ultimately help to improve the
quality of these interventions themselves.
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Key Points
We developed a 43-item checklist, entitled the
RIMES statement, to assess the reporting quality of
risk minimization evaluation studies in order to
support more standardized, transparent reporting
study results.
Our findings showed that the checklist had good
inter-rater reliability, both overall and for the four
subscales (Key information; Design;
Implementation; and Evaluation).
We conclude with a proposal for further validating
and refining the checklist to increase its practical
appeal and usefulness.
1 Introduction
Ensuring the safe and appropriate use of medicines is an
important public health priority, particularly in light of the
rapid growth worldwide in prescription drug use [1].
Although product labeling serves as the basis for safe
medication use, additional measures to minimize risks can
be mandated by regulatory authorities in certain circum-
stances for products with serious safety concerns [2, 3].
These risk minimization programs can be imposed as either
a condition of marketing authorization approval (most
commonly), or as a condition to permit continued mar-
keting authorization.
Marketing authorization holders of medicinal products
are responsible for designing, implementing and evaluating
these programs. Typically, however, sponsors must rely on
healthcare professionals (alone or in conjunction with other
third parties such as continuing medical education provi-
ders) to implement the actual intervention components
[4, 5]. Other defining hallmarks of risk minimization
interventions include the fact that they target multiple
audiences (e.g. healthcare professionals, patients, care-
givers, lay audiences), feature multiple measures or
‘components’ (e.g. risk communication, training of
healthcare professionals, prescriber certification), span a
range of socioecological levels (e.g. individual patient,
healthcare system), involve multiple different types of
implementers (e.g. physician prescriber, pharmacist,
informal caregivers), and require implementation across
multiple settings (e.g. inpatient, outpatient, home) and
geographic areas (e.g. regions, countries, urban, rural).
Collectively, these characteristics define what is known
as a ‘complex’ intervention [6]. Evaluating complex
interventions requires ascertaining not only whether the
actual intervention achieved the desired impact, but under
what conditions it did so, for whom, and whether the
impact was sustained over time [7]. Undesired or unan-
ticipated impacts may also need to be captured, such as
discontinuation of treatment or channeling towards inap-
propriate or suboptimal treatments.
Evidence of risk minimization program effectiveness is
critical for demonstrating to regulatory authorities that a
product’s benefit-risk balance remains positive. Sponsors
are encouraged to publish the results of their risk mini-
mization program evaluations in order to build the risk
minimization evidence base [3]. Additionally, the Euro-
pean Medicines Agency is legally required to make public
both the protocols and abstracts of results of the post-au-
thorization safety studies initiated, managed or financed by
a marketing authorization holder, including those on risk
minimization effectiveness [8].
Improving the effectiveness of risk minimization pro-
grams is a priority within the pharmacovigilance commu-
nity [7–9]. However, to date, the number of risk
minimization evaluation studies reported in the peer-re-
viewed literature has lagged far behind the number that
have been implemented thus far [10]. Of those evaluations
that have been published, methods and results have been
inconsistently reported, making it difficult to evaluate their
methodological quality and to interpret the results [11].
Common shortcomings in reporting include a failure to
specify the intervention’s purported causal mecha-
nism(s) of risk minimization intervention and its relation to
short-, intermediate- and long-term intended outcomes,
inadequate information regarding the process of imple-
mentation and the healthcare context in which the inter-
vention was delivered, limited correspondence between the
stated intervention aim and the selected effectiveness
measures, and an absence of predefined thresholds for
effectiveness determination [12].
Over the past decade, numerous reporting checklists
have been developed to standardize reporting of results of
different types of studies, thereby building the evidence
base for clinical and public health practices. Such check-
lists include, for example, CONSORT (clinical trials),
STROBE and GRACE (observational and epidemiological
studies), TREND (public health intervention evaluation
studies), SQUIRE (healthcare systems), WIDER (knowl-
edge transfer), and GREET (educational interventions and
teaching) [13–20]. Recently, there has been a call to
improve the evidence base also underlying risk minimiza-
tion interventions [3, 11, 21]. In order to address this call, a
standard is needed for gauging the reporting quality of risk
minimization evaluation studies. Notably, however,
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existing reporting checklists have limited applicability for
the purposes of assessing the reporting quality of risk
minimization evaluation studies. First, such checklists
focus either on randomized designs or on one particular
type of non-randomized design. To date, experimental
study designs (e.g. randomized controlled trials), have not
been used for the purposes of evaluating risk minimization
programs because regulators have required that these pro-
grams be implemented across the entire targeted popula-
tion. As a result, a variety of other non-randomized types of
designs have been used (e.g. observational, interrupted
times series), including mixed methods approaches that
combine both qualitative (how, why) and quantitative (how
much) research in order to gain a fuller understanding of
the risk minimization program impact and the factors that
contributed to its success or failure [11].
Extant checklists also fail to address why and how
specific risk minimization program measures were selec-
ted, how they were designed, the process and context of
program implementation, who was reached by the inter-
vention, what ‘dosage’ amount was received (i.e. degree of
exposure to program activities, such as, for example,
completing all educational requirements), whether and to
what extent different healthcare delivery settings adopted
the program, and the degree to which intervention delivery
was sustained over time. In particular, both the process and
context of implementation are important to assess because
risk minimization interventions, unlike clinical trials, are
conducted under ‘real-world’ conditions in which both
participants and participating settings are heterogeneous,
implementers vary in terms of degree of commitment and
relevant skills or expertise, and time and other resources
are constrained. Information on the process and context of
implementation can shed light on the mechanism(s) of
change, help identify the circumstances under which the
intervention works best, and aid in interpreting evaluation
results, including negative, inconclusive, or positive inter-
vention effects. Not least, it can also provide insight on
unintended effects, whether negative or positive in nature
[7, 22].
To address this gap, the Benefit-Risk Assessment,
Communication, and Evaluation (BRACE) Special Interest
Group (SIG) of the International Society for Pharma-
coepidemiology (ISPE) sought to develop a common set of
criteria to assess the quality of information reported in risk
minimization evaluation studies [22, 23]. These criteria,
designated as the Reporting recommendations Intended for
pharmaceutical risk Minimization Evaluation Studies
(RIMES) statement, were intended for use by regulatory
bodies, industry, academic and journal editors and
reviewers. The goals of the checklist were to (1) assess the
quality of risk minimization evaluation studies; (2)
improve the interpretation and usefulness of risk
minimization evaluation study results; (3) increase aware-
ness among key stakeholders regarding evidence-based
standards in the field of risk minimization; (4) establish a
reporting platform that bridges across the relevant sciences,
including public health, health communication science,
behavioral medicine, health services research and phar-
macoepidemiology; and (5) promote, via reporting stan-
dardization and quality improvement, the inclusion of
published risk minimization evaluation studies into sys-
tematic reviews. The latter goal is especially important
given the paucity of published literature on risk mini-
mization evaluation studies by drug or drug class. In this
regard, the RIMES statement could help facilitate sys-
tematic reviews of evaluations of specific categories of risk
minimization interventions (e.g. those pertaining to con-
trolled distribution systems or healthcare provider com-
munication plans), such as have been conducted for
different types of behavioral health interventions [24].
The RIMES statement was developed explicitly as a tool
for assessing the quality of the information reported in risk
minimization evaluation studies, not as a checklist for
evaluating the quality of these studies themselves. Ulti-
mately, however, widespread adoption of the RIMES
statement could lead to improvements in the quality of
evaluation study design and, in so doing, generate better
evidence on the effectiveness of risk minimization inter-
ventions for regulatory decision making. In turn, better
evidence regarding the effectiveness of risk minimization
interventions—which programs, for example, work best for
whom and under what circumstances—should enhance the
quality of risk minimization programs themselves [16]. The
purpose of this study was to develop an initial version of
the RIMES statement and test its reliability in a sample of
recently published risk minimization evaluation studies.
2 Methods
We convened a multidisciplinary team of professionals
(authoring team) with expertise in therapeutic risk man-
agement, regulatory science, public health, pharmacoepi-
demiology and behavioral medicine to develop the
checklist. The development process involved a series of
four consecutive steps consisting of (1) initial development
of a checklist; (2) piloting; (3) individual checklist item
revisions; and (4) inter-rater reliability testing. These steps
are described in greater detail below.
2.1 Development of the Initial Version
of the Checklist
The initial development of the checklist was guided by a
theoretical framework, a review of existing reporting
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checklists, and leading texts on public health and risk
minimization intervention design, implementation and
evaluation [14, 16, 25–34].
2.1.1 Theoretical Framework
To develop the RIMES statement, we adapted and com-
bined relevant elements from existing program theory and
process evaluation frameworks [7, 21, 35]. Our resulting
framework (Fig. 1) emphasizes the stepwise contribution
of design, implementation, and evaluation to the effec-
tiveness of a complex intervention. Furthermore, it high-
lights the role of ecological context as an important
contributor to intervention outcomes [32, 35]. Each of the
items in our RIMES checklist falls within the elements of
this framework. For example, a risk minimization program
may be implemented in a range of outpatient care settings,
each of which could differ in terms of leadership com-
mitment to implementation, quality of staff training, and
operating resources. An understanding of the role of, and
interactions among, different contextual factors can also
provide insight regarding how to optimize the fit of a risk
minimization intervention to different delivery settings and
how to improve its sustainability (i.e. long-term delivery)
[36].
2.1.2 Existing Checklists
Many of the items included in the RIMES checklist refer to
general research standards and are common to existing
reporting checklists [14, 16, 17] but have been tailored to
apply specifically to risk minimization. Items common to
such reporting checklists relate to key information (author
names, affiliations, conflict of interests, funding), descrip-
tions related to study methods (participant recruitment,
sample size, details of interventions, description of mea-
sures, and statistical analyses) and reporting of results
(main results, limitations, generalizability and conclu-
sions). We also consulted a checklist for implementation
(Ch-IMP) and incorporated similar concepts (process
metrics, implementer training, fidelity, adoption) into the
RIMES checklist [7].
2.1.3 Leading Texts in Public Health and Risk
Minimization
There are a number of known challenges to risk mini-
mization programs and an emerging consensus regarding
ways to advance the science in this field [11, 33]. For
example, experts suggest that the goals of the intervention
should be clearly defined, specific, measureable and time-
bound. Thresholds of success should be determined a pri-
ori. When developing tools for communication, content
should be tested among stakeholders (including intended
audience) to ensure the message of risks is clearly con-
veyed. Furthermore, evaluations should address process
outcomes (reach, adoption, implementation), as well as
examine the results in the short term (effectiveness) and the
success of the message in the long term (maintenance and
sustainability). Each of these concepts helped inform the
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contents of the draft RIMES checklist
[9, 11, 14, 16, 25–34, 37].
2.2 Piloting
To explore this concept, we conducted an initial literature
search of peer-reviewed published articles pertaining to
formal risk minimization programs and evaluations.
Specifically, we searched PubMed for English-language
articles published between January 2000 and July 2016
using the following text words: (‘risk minimization plan’
OR ‘risk evaluation and mitigation strateg*’ OR ‘risk
management plan’ OR ‘risk minimization’ OR ‘risk min-
imisation’ OR ‘direct healthcare professional communica-
tion*’ OR ‘dear doctor’ OR ‘risk communication’.
Based on this literature search, we identified a conve-
nience sample of 12 articles that met the following inclu-
sion criteria: article relates to (1) a pharmaceutical product,
(2) a risk communication or risk minimization intervention
(including written, verbal or electronic), and (3) an
assessment of the impact of the intervention [4, 5, 38–47].
Two raters (co-authors MYS and AR) separately reviewed
and applied the draft checklist to each article. Of these two
raters, MYS was an experienced researcher with extensive
subject matter expertise. Conversely, AR had formal
training and experience conducting health information
communication research, but comparatively limited expe-
rience (less than 1 year) in designing and evaluating
pharmaceutical risk minimization programs specifically.
2.3 Individual RIMES Checklist Item Revisions
and Development of the Revised Checklist
Following the independent review of the 12 articles and
application of the draft version of the RIMES checklist, the
two raters met to discuss and compare item ratings. Based
on that discussion, the checklist was further refined and the
wording of several items was clarified to reduce ambiguity
and to reflect single concepts only. Several examples were
also added to guide future checklist application. The
updated version of the checklist contained 45 items, with
answer options scored as 0 (not reported or not applicable)
or 1 (reported). These items were grouped into four
domains:
1. Key information—includes established reporting crite-
ria items such as adequate title, appropriate summary
of the study in the abstract, valid, evidence-based study
conclusions, and reporting of limitations as well as
disclosures of funding and conflicts of interest.
2. Description of the risk minimization program—in-
cludes items that adequately describe the risk
minimization program, such as the objective, design,
target population and other key program elements.
3. Implementation of the risk minimization program—
includes items that describe program implementation
planning considerations, and how the program was
implemented.
4. Evaluation of the risk minimization program—in-
cludes items that describe the study rationale, methods,
implementation process measures, in particular the
extent to which the program was implemented accord-
ing to plan, and any factors that might have served to
facilitate or impede implementation efforts, outcome
measures and study results.
2.4 Inter-Rater Reliability Testing of the Revised
Checklist
A second literature search of the published risk mini-
mization evaluation literature was conducted approxi-
mately 6 months after the original search. The same search
terms were employed. The inclusion criteria were the same
as those used in the initial round of testing with two
exceptions: (1) emphasis was placed on identifying only
those articles evaluating risk minimization interventions
formally required by a regulatory authority; and (2) the
search timeframe was narrowed to include only those
articles that had been published between January 2013 and
January 2017. The purpose of restricting the timeframe was
to focus the search on more recent studies that were
expected to have higher reporting quality, given that they
had been requested by a regulatory authority and had been
published in the wake of European Union (EU) pharma-
covigilance legislation that provided guidance on how
sponsors were to evaluate formal risk minimization com-
mitments. For the inter-rater reliability testing, we selected
a convenience sample of the first 10 articles that met all the
inclusion criteria (Table 1) [4, 5, 45–52].
The two raters independently reviewed the 10 articles,
applying the revised checklist. Inter-rater reliability was
reported using Cohen’s kappa and Gwet’s AC1 statistics.
Statistical analysis was conducted in R version 3.3.2 using
the ‘irr’ and ‘lpSolve’ packages. Interpretation of both
statistics was based on Cohen’s definition of agreement:
poor (0), slight (0.01–0.20), fair (0.21–0.40), moderate
(0.41–0.60), substantial (0.61–0.80), and almost perfect
(0.81–1.0) [53]. Reporting inter-rater reliability with the
kappa statistic is appropriate when the ratings have varia-
tion. The kappa statistic is sensitive to a high frequency of
one score over another and may yield low reliability even
when the percentage of agreement is high. This issue is
known as the ‘kappa paradox’ and is described by Feinstein
and Cicchetti [54]. In 2008, Gwet proposed and validated
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Table 1 Description of articles reviewed with the RIMES statement
First author Year Study design N Risk communication
intervention
Purpose of evaluation study
Bester et al.
[48]
2016 Cross-sectional survey to assess
awareness of brochure and
understanding of brochure
information
121 healthcare
professionals
Brochure highlighting new
and important adverse
events
Conducted to determine the
effectiveness of the
educational brochure
Blanchette et al.
[52]
2015 Analysis of pharmacy claims and
medical claims for laboratory
services at the time of drug
initiation and within specified
time intervals
Data from 742
patients
prescribed
medication
REMS elements including a
dear doctor letter
Conducted to fulfill REMS
commitment
Brody et al.
[49]
2015 Cross-sectional survey of
physicians to assess receipt of
brochure and self-reported
behaviors; analysis of EMR
data
800 healthcare
providers
surveyed; Data
from 7040
patients via
EMR
Educational materials to
inform practitioners of label
changes and risks of the
medication
Conducted to fulfill the Dutch
Medicines Evaluation Board
commitment
Cepeda et al.
[4]
2016 Annual cross-sectional surveys of
healthcare professionals and
patients; drug utilization study
of prescribing patterns;
surveillance of abuse, misuse
overdose, addiction and death
associated with extended-
release/long-acting opioids
Surveys: 612
healthcare
professionals
and 423
patients
Educational training course
on safe and appropriate
prescribing and use of
extended-release/long-
acting opioids
Conducted to fulfill REMS
commitment
DiSantostefano
et al. [51]
2017 Retrospective observational study
of drug utilization via pharmacy
data and employer-based claims
data
Not
applicable—
all dispensing
of medications
across 7 years
REMS, including
communication plan with
letters to prescribers,
printed and web-based
information for HCPs, and
letters to professional
societies
Conducted to fulfill REMS
commitment
Enger et al. [45] 2013 Retrospective analysis of Optum
Research Database (US
administrative claims database)
3568 patients Medication guide Conducted to fulfill REMS
commitment
Hollingsworth
et al. [46]
2016 Retrospective analysis of
Medicare 5% sample dataset
Pre-REMS
cohort: 1252
patients; post-
REMS cohort:
949 patients
Black-box warning; other
REMS materials not
specified
Conducted to fulfill REMS
commitment
Kraus et al. [5] 2013 Pre-test/post-test learning
assessment
176,988
healthcare
professionals
CME activity educational
materials versus safe use
alert
Conducted to fulfill REMS
commitment
Smith et al. [47] 2012 Cross-sectional surveys 915 healthcare
professionals
Distribution of product safety
monograph, TB screening
guidelines and TB
screening checklist
Conducted to fulfill EMA
‘additional risk
minimization’ PASS
commitment
Tong et al. [50] Pre-post intervention assessment
of number of reported adverse
drug reactions
36 cases of
adverse events
REMS included prescribing
program and medication
guide
To examine incidence of AEs,
trends in occurrence of AEs
over a 9-year period, and
clinical characteristics
associated with AEs. To
assess effectiveness of the
REMS program
REMS risk evaluation and mitigation strategies, EMR electronic medical record, HCPs healthcare providers, CME continuing medical education,
TB tuberculosis, EMA European Medicines Agency, PASS post-authorization safety study, AEs adverse events
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the AC1 statistic as a way to address the limitations of
kappa [55]. This statistic is less influenced by skewed
ratings and is based on an alternative adjustment of chance
that is defined as the ‘‘conditional probability that two,
randomly selected rates will agree, given that no agreement
will occur by chance’’ [56]. The Gwet’s AC1 method has
been used in other evaluations of inter-rater reliability of
checklists and is often presented in conjunction with the
kappa coefficient [7, 57, 58].
3 Results
The RIMES checklist was developed and then underwent
two rounds of pilot testing. As a result of the inter-rater
reliability analysis in the second round of testing, two items
were deleted due to ambiguity in their phrasing—ambi-
guity that contributed to differing interpretations and poor
inter-rater reliability. These items were (1) ‘Explicit
statement of causal assumptions linking intervention to a
benefit for the recipient is provided’, and (2) ‘Upfront
efforts to address potential sources of bias and confound-
ing’. Based on further discussion, it was ultimately con-
cluded that the first item substantially overlapped with an
earlier item in the checklist (‘Theoretical basis of the risk
minimization program’). In addition, the second item was
deemed as more accurately reflecting a quality study design
item and, as such, covered by an earlier item (‘Internal
validity. Evaluation limitations, degree to which sources of
potential bias were addressed’). After these eliminations,
our final checklist consisted of 43 items (Table 2).
Rater scoring, percentage agreement, and reliability
statistics for individual items can be found in Table 3. The
frequency of each rater’s scores are listed, where Y or N
indicate the number of articles in which the rater deter-
mined the item was adequately covered or absent, respec-
tively. For example, for Item 2b, Rater 1 determined nine
articles fulfilled the criteria and one article did not fulfill
criteria. For individual items, inter-rater agreement ranged
from 40 to 100%, kappa coefficients ranged from - 0.15 to
1.00, and AC1 coefficients ranged from - 0.20 to 1.00.
Slightly more than half (n = 22) of the kappa coefficients
ranged from moderate to almost perfect, and slightly less
than half were either fair (n = 10), slight (n = 2) or poor
(n = 7). Two items (9b and 17f) had negative kappa
coefficients, indicating that the reliability of raters was
lower than what would be expected due to chance.
The reliability statistics for a number of items showed
large discrepancies despite high or moderate percentage
agreement (items 2b, 3b, 4, 5a, 8, 10a, 13a, 17f). For
instance, for all of the kappa coefficients rated as poor or
negative in value, the percentage agreement ranged
between 70 and 90% and the AC1 statistic was 0.59 or
higher. For these items, the raters’ scoring patterns showed
a high degree of skew such that either the item was scored
consistently as being present or scored consistently as
being absent.
One item resulted in 40% agreement, a slight kappa
(0.12) and a negative AC1 statistic. This item passed the
initial piloting of the checklist but emerged as a source of
discordant ratings between the raters during reliability
testing. During the final round of testing, the raters dis-
agreed on the specificity required to give full credit on this
item, with one rater being consistently more stringent than
the other.
Summary statistics for the checklist overall and for
subscales can be found in Table 4. We found the inter-rater
reliability of the checklist overall to be substantial
(j = 0.65, AC1 = 0.65). Similarly, three of the four
domains also showed substantial reliability based on the
kappa: key information (j = 0.73, AC1 = 0.80), design
(j = 0.64, AC1 = 0.64), and evaluation (j = 0.66,
AC1 = 0.69). The implementation domain (j = 0.17,
AC1 = 0.61) resulted in slight reliability based on the
kappa coefficient, but higher reliability based on the AC1.
3.1 Respondent Burden
Initially, the average time raters spent reviewing and rating
each article using the checklist was approximately 25 min;
however, as familiarity with the checklist items increased,
the average review time dropped to approximately 20 min
per article.
4 Discussion
This article reports on the development of a set of criteria
to describe the reporting quality of risk minimization
intervention evaluation studies. Our results show that it is
feasible to develop such a checklist despite the fact that
these studies, by definition, must utilize non-randomized
design types, may feature two or more substudies, and may
employ a combination of both qualitative and quantitative
research methods (‘mixed methods’) [4]. The checklist
addresses important aspects of reporting that are vital to
assessing the quality of a risk minimization evaluation
study and that are under-represented in existing reporting
checklists developed for other types of research studies and
program evaluations. Examples of such key aspects include
a description of the goals of the risk minimization program
and the actual risk minimization measures used, how the
program was implemented and whether implementation
efforts were successful, and the inclusion of information
regarding the external validity of evaluation results.
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Table 2 RIMES statement: checklist of items that should be included in reports of risk minimization evaluation studies for medicinal products
Domain Topic Item Descriptor and relevant examples
Key
information
Declarations 1 Name(s) and affiliation(s) of the study sponsor(s) in the Conflicts of Interest statement
and/or Acknowledgments statement
Title and abstract 2a Title mentioning type of evaluation study design, name of medicinal product(s), and
target population/healthcare setting (all three required)
Example: A drug utilization study to assess dispensing patterns at pharmacies for [drug
name]
2b Structured abstract describing the purpose of the intervention and target recipient(s),
evaluation methods, results and conclusions
Discussion 3a Summary of key results with reference to study objectives
3b Internal validity. Evaluation limitations, degree to which sources of potential bias were
addressed, including both the direction and magnitude of any potential bias
3c External validity and generalizability (e.g. Will the intervention work across diverse
populations and settings?)
3d Likelihood of sustainability. Discussion of the degree to which the intervention was
integrated into the delivery setting (e.g. policies or incentives put in place to support
ongoing intervention maintenance)
Funding 4 Sources of evaluation study funding and other support, role of funders
Intervention
Design
Design 5a Goals and objectives of the risk minimization intervention
5b Implementation date of the risk minimization intervention
5c Theory or theories used to design intervention and/or risk minimization tools, including
the expected causal pathway for intervention impact
Example: The intervention was based on the theory of reasoned action
Target population 6 Description of the key characteristics of geography and population targeted for
intervention (i.e. age, sex, race/ethnicity, disease condition, socioeconomic status),
enabling the reviewer/reader to determine if the evaluation study sample adequately
reflected the targeted population
Example: The risk minimization program targeted at US adults (aged 18 years ?) who
have been prescribed [drug name] for the treatment of cardiovascular disease
Risk minimization tool
selection and development
7a Risk minimization tool(s) [e.g. managed distribution program; Medication Guide]
Example: The risk minimization tools included a Dear HealthCare Professional Letter,
and a Benefit-Risk Counseling tool for physicians
7b Pilot testing and formative evaluation of tools
7c Cultural sensitivity (i.e. reporting regarding whether local language, sociocultural
values and traditions were considered when designing tools)
7d Stakeholder engagement, (i.e. patient and other stakeholder input considered/obtained in
design of tools
7e Risk minimization tool message content (could be included in an online supplement or
appendix)
Example: Information on [drug name] risks, symptoms to watch for, and actions to take
if symptoms presented themselves
7f Intervention distribution modality, including rationale for why a specific modality/ies
were selected (the latter is recommended but not essential)
Example: The tool was intended for distribution via Medscape email to physicians,
journal advertisements, and a website posting
Success metrics 8 A priori specification of measures and threshold for determination of intervention
success
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Table 2 continued
Domain Topic Item Descriptor and relevant examples
Implement-
ation
Setting 9a Organizations responsible for implementing the intervention
9b Implementers of risk minimization intervention, including, for example, how they were
selected and their qualifications
9c Training (i.e. did implementers receive training in the intervention and how to
implement it?)
9d Ecological context (i.e. healthcare settings where the intervention was implemented
(number, type and location[s])
Fidelity 10a Use of a formal protocol for implementing the intervention
10b Important intentional modifications made to risk minimization intervention after
commencement (including at local level)
Evaluation Hypotheses 12 Specific goals/objectives of the risk minimization evaluation study, including any
hypotheses
Example: We hypothesized that, as a result of distributing a brochure, 80% of
physicians who prescribed [drug name] would correctly identify the three key steps
involved in screening patients for low blood pressure prior to initiating [drug name]
therapy
Participants 13a Eligibility requirements (i.e. inclusion and exclusion criteria) for participating in the
evaluation study
Example: Physicians were eligible to participate in the evaluation if they had
prescribed [drug name] to 10? patients within the last 6 months
13b Method of participant recruitment into evaluation study, including whether financial
reimbursement was provided (code as zero for exceptions, e.g. secondary data
analysis)
Measures 14a Process evaluation measures prespecified as a goal of the evaluation (e.g. reach,
adoption, dose delivered, fidelity of implementation)
14b Primary and secondary outcome measures
14c Explicit link between evaluation study goals and methods in particular, and selection of
processes and outcome measures
14d Sources of data and methods of measurement for each variable of interest
Statistical analysis 15a Study size calculation and power analysis (as applicable, depending on whether the
study is qualitative or quantitative)
15b Statistical methods for analysis of primary and secondary outcomes
15c Explanation of missing data handling
Results: process measures 16a Results for each process evaluation measure
16b Description of factors that served to impede or facilitate intervention adoption and
implementation
Results: main outcomes 17a A table showing baseline characteristics of the evaluation participants and evaluation
settings (e.g. demographic, clinical, social, setting type, number and locations)
17b Results of participant recruitment (for human subjects research only), including dates
and reasons for non-response or attrition rates (a participant flow diagram is strongly
recommended but not required, not applicable for analysis of secondary dataset)
17c Description of primary and secondary outcome results
17d Precision of reporting of outcomes (e.g. 95% confidence interval) [as applicable, see
above]
17e Description of whether primary outcome(s) exceeded a specified success threshold (as
applicable, see above)
17f Results of any other analyses performed, including subgroup analyses, interactions and
sensitivity analyses, distinguishing pre-specified from exploratory, identification of
unintended impact of the risk minimization intervention or the evaluation study
The RIMES Statement 397
The RIMES statement is intended for use by a range of
audiences, including regulatory, industry, academic eval-
uators and journal editors. Standardized reporting of risk
minimization evaluation studies, such as that provided by
the RIMES statement, can facilitate systematic reviews and
data synthesis, including meta-analyses. This is a
Table 3 Inter-rater reliability testing: percentage agreement, Kappa and AC1 statistics by item
Subscale Item Rater 1 Rater 2 Percentage agreement Kappa AC1 statistic
Key information 1 Y: 10 N: 0 Y: 10 N: 0 100 1.00 1.00
2a Y: 2 N: 8 Y: 2 N: 8 80 0.38 0.71
2b Y: 9 N: 1 Y: 10 N: 0 90 0 0.89
3a Y: 10 N: 0 Y: 10 N: 0 100 1.00 1.00
3b Y: 9 N: 1 Y: 10 N: 1 90 0 0.89
3c Y: 4 N: 6 Y: 3 N: 7 70 0.35 0.45
3d Y: 2 N: 8 Y: 1 N: 9 90 0.62 0.87
4 Y: 9 N: 1 Y: 10 N: 0 90 0 0.89
Intervention description 5a Y: 10 N: 0 Y: 8 N: 2 80 0 0.76
5b Y: 9 N: 1 Y: 7 N: 3 80 0.41 0.71
5c Y: 0 N: 10 Y: 0 N: 10 100 1.00 1.00
6 Y: 3 N: 7 Y: 1 N: 9 80 0.41 0.71
7a Y: 8 N: 2 Y: 7 N: 3 70 0.21 0.52
7b Y: 8 N: 2 Y: 9 N: 1 90 0.62 0.87
7c Y: 0 N: 10 Y: 0 N: 10 100 1.00 1.00
7d Y: 2 N: 8 Y: 1 N: 9 90 0.62 0.87
7e Y: 6 N: 4 Y: 9 N: 1 70 0.29 0.52
7f Y: 6 N: 4 Y: 6 N: 4 60 0.17 0.23
8 Y: 0 N: 10 Y: 2 N: 8 80 0 0.76
Implementation 9a Y: 2 N: 8 Y: 8 N: 2 40 0.12 - 0.20
9b Y: 2 N: 8 Y: 1 N: 9 70 - 0.15 0.60
9c Y: 0 N: 10 Y: 0 N: 10 100 1.00 1.00
9d Y: 4 N: 6 Y: 1 N: 9 70 0.29 0.52
10a Y: 1 N: 9 Y: 0 N: 10 90 0 0.89
10b Y: 3 N: 7 Y: 2 N: 8 70 0.21 0.52
Evaluation 12 Y: 10 N: 0 Y: 10 N: 0 100 1.00 1.00
13a Y: 7 N: 3 Y: 10 N: 0 70 0 0.59
13b Y: 5 N: 5 Y: 4 N: 6 70 0.40 0.41
14a Y: 3 N: 7 Y: 3 N: 7 80 0.52 0.66
14b Y: 10 N: 0 Y: 10 N: 0 100 1.00 1.00
14c Y: 7 N: 3 Y: 7 N: 3 100 1.00 1.00
14d Y: 10 N: 0 Y: 10 N: 0 100 1.00 1.00
15a Y: 3 N: 7 Y: 1 N: 9 80 0.41 0.71
15b Y: 8 N: 2 Y: 9 N: 1 90 0.62 0.87
15c Y: 2 N: 8 Y: 1 N: 9 90 0.62 0.87
16a Y: 5 N: 5 Y: 3 N: 7 80 0.60 0.62
16b Y: 2 N: 8 Y: 5 N: 5 70 0.40 0.45
17a Y: 7 N: 3 Y: 6 N: 4 70 0.35 0.45
17b Y: 3 N: 7 Y: 6 N: 4 70 0.44 0.41
17c Y: 10 N: 0 Y: 10 N: 0 100 1.00 1.00
17d Y: 8 N: 2 Y: 8 N: 2 80 0.38 0.71
17e Y: 1 N: 9 Y: 3 N: 7 80 0.41 0.71
17f Y: 9 N: 1 Y: 9 N: 1 80 - 0.11 0.71
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particularly important feature given that, to date, pharma-
ceutical risk minimization has been singularly uninformed
by research findings from other relevant sciences, including
public health, communication, behavioral medicine and
health services research. In addition, the checklist can
guide research planning and manuscript development in the
first instance, and serve as a platform for bridging phar-
maceutical risk minimization science with other relevant
fields. Not least, it can also assist sponsors in designing
higher-quality risk minimization evaluation studies, and
through learning from this evidence may potentially
enhance the quality and effectiveness of risk minimization
programs themselves.
The main limitation of this study related to the relatively
small size (n = 10) of the sample of articles reviewed by
only two reviewers. With a larger sample of articles or
additional reviewers, both the kappa and AC1 statistics
would have been more reliable and the rates of discrepancy
between them would have been reduced. However, as
noted previously, we were limited in our sample size by the
relative paucity of articles on risk minimization evaluation
studies that have been published in the peer-reviewed lit-
erature to date.
5 Conclusions
Results of preliminary reliability testing show that the
RIMES statement has good inter-rater reliability among a
small sample of articles. Important next steps in its
development would include conducting testing among a
larger sample to confirm item reliability, particularly for
items in this analysis that have low kappa coefficients. It is
possible some items are underperforming and may require
adjustment. In addition, formal usability testing and an
examination of both the content and construct validity of
the checklist based on a more comprehensive and sys-
tematic assessment of relevant publications, including
those found in the grey literature. To enhance the check-
list’s practicality, future research should also assess ways
to streamline it further, potentially via factor analytic
methods, and to explore possible approaches to item
weighting. Not least, to aid in standardizing the interpre-
tation of checklist items, a user manual should be
developed.
Although additional methodological work is planned,
the current version of the checklist showed good reliability
when tested by two raters among a small sample of articles.
As such, this checklist represents an important step forward
in improving the quality of reporting of risk minimization
evaluation studies, one that can benefit both the science of
pharmaceutical risk minimization and, ultimately, patient
safety.
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